These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing. Sarayani A; Hampp C; Brown JD; Donahoo WT; Winterstein AG Drug Saf; 2022 Dec; 45(12):1517-1527. PubMed ID: 36318419 [TBL] [Abstract][Full Text] [Related]
45. Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Milano W; De Biasio V; Di Munzio W; Foggia G; Capasso A Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1232-1243. PubMed ID: 32410565 [TBL] [Abstract][Full Text] [Related]
46. Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Review of the literature and lessons learned from adults. Bensignor MO; Kelly AS; Arslanian S Front Endocrinol (Lausanne); 2022; 13():1043650. PubMed ID: 36387846 [TBL] [Abstract][Full Text] [Related]
47. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia). Shyh G; Cheng-Lai A Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809 [TBL] [Abstract][Full Text] [Related]
51. THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE. Shibuya K; Ali KF; Ji X; Milinoivh A; Bauman J; Kattan MW; Pantalone KM; Burguera B Endocr Pract; 2019 Oct; 25(10):1022-1028. PubMed ID: 31241358 [No Abstract] [Full Text] [Related]
52. Drug treatment of obesity in the cardiovascular patient. Charakida M; Tousoulis D; Finer N Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924 [TBL] [Abstract][Full Text] [Related]
53. Pharmacotherapy in pediatric obesity: current evidence and landscape. Singhal V; Sella AC; Malhotra S Curr Opin Endocrinol Diabetes Obes; 2021 Feb; 28(1):55-63. PubMed ID: 33186194 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Lei XG; Ruan JQ; Lai C; Sun Z; Yang X Obesity (Silver Spring); 2021 Jun; 29(6):985-994. PubMed ID: 33864346 [TBL] [Abstract][Full Text] [Related]
56. Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study. Guerdjikova AI; Williams S; Blom TJ; Mori N; McElroy SL Innov Clin Neurosci; 2018 Jun; 15(5-6):17-21. PubMed ID: 30013815 [No Abstract] [Full Text] [Related]
57. Use of phentermine-topiramate extended release in combination with sleeve gastrectomy in patients with BMI 50 kg/m Ard JD; Beavers DP; Hale E; Miller G; McNatt S; Fernandez A Surg Obes Relat Dis; 2019 Jul; 15(7):1039-1043. PubMed ID: 31147285 [TBL] [Abstract][Full Text] [Related]
58. New pharmacological treatments for the management of obesity. Hurt RT; Edakkanambeth Varayil J; Ebbert JO Curr Gastroenterol Rep; 2014; 16(6):394. PubMed ID: 24828101 [TBL] [Abstract][Full Text] [Related]
59. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618 [TBL] [Abstract][Full Text] [Related]
60. Current and future pharmacotherapies for obesity in children and adolescents. Kelly AS Nat Rev Endocrinol; 2023 Sep; 19(9):534-541. PubMed ID: 37337008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]